Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human leukemic "null" cell line (NALL-1).

S Hiraki, I Miyoshi, I Kubonishi

    Cancer
    |November 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Radiomics analysis of peri-implant bone alterations after dental implant fracture.

    International journal of oral and maxillofacial surgery·2026
    Same author

    The Relationship between Psychological Distress and Physical Frailty in Japanese Community-Dwelling Older Adults: A Cross-Sectional Study.

    The Journal of frailty & aging·2023
    Same author

    COVID-19 transmission in dental and oral/maxillofacial surgical practice during pandemic: questionnaire survey in 51 university hospitals in Japan.

    The Journal of hospital infection·2022
    Same author

    Odontogenic chronic rhinosinusitis patients undergoing tooth extraction: oral surgeon and otolaryngologist viewpoints and appropriate management.

    The Journal of laryngology and otology·2020
    Same author

    Physical Frailty and Risk of Needing Long-Term Care in Community-Dwelling Older Adults: a 6-Year Prospective Study in Japan.

    The journal of nutrition, health & aging·2019
    Same author

    Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019

    Researchers established the NALL-1 cell line from acute lymphoblastic leukemia (ALL) patient blood. This unique human leukemic "null" cell line offers distinct characteristics for cancer research.

    Area of Science:

    • Hematology
    • Cell Biology
    • Oncology

    Background:

    • Acute lymphoblastic leukemia (ALL) is a significant hematologic malignancy.
    • Established cell lines are crucial for understanding leukemia biology and developing therapies.
    • Previous cell lines often possess T or B cell properties or Epstein-Barr virus (EBV) contamination.

    Purpose of the Study:

    • To establish and characterize a novel human leukemic cell line from an ALL patient.
    • To differentiate this new line from existing EBV-positive lymphoblastoid cell lines.
    • To highlight the potential utility of this unique cell line in leukemia research.

    Main Methods:

    • Isolation of cells from peripheral blood of an ALL patient.
    • Cytogenetic, morphologic, and functional analyses of the established cell line.

    Related Experiment Videos

  • Comparison of NALL-1 characteristics with known lymphoblastoid cell lines.

    • Main Results:

    • Successfully established the NALL-1 human lymphoblast cell line.
    • NALL-1 cells lacked T and B cell properties and were EBV-negative.
    • Demonstrated distinct cytogenetic, morphologic, and functional features compared to previously reported lines.
    • Identified NALL-1 as the first human leukemic "null" cell line derived from ALL.

    Conclusions:

    • The NALL-1 cell line represents a valuable new resource for studying human acute lymphoblastic leukemia.
    • Its unique "null" cell characteristics offer a distinct model for investigating leukemia origins and mechanisms.
    • Further research utilizing NALL-1 is expected to advance understanding and treatment of ALL.